FDA APPROVES TRIALS FOR OBECURE OBESITY DRUG

A A

Bio Light Israeli Life Sciences has received approval from the FDA to apply for permission to proceed directly to Phase II clinical trials of its obesity drug, without first completing Phase I preliminary safety testing.

Obecure will file its application for Phase II clinical trials with the FDA next month and has already held talks with several medical centers in the U.S., which will conduct trials locally and recruit patients. Obecure said it expected that patients participating in the trials would begin testing the drug within three months. It added that it already completed the preliminary laboratory tests required by the FDA, prior to the commencement of the Phase II trials and these revealed that the drug was not toxic and did not contain any potential carcinogenic elements.